How MBA was paid
$12.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Paul B. Bolno, M.D., MBAPresident and Chief Executive Officer | $700,000 | $1,420,540 | $9,506,300 | $614,250 | $36,826 | $12,277,916 |
| Kyle Moran, CFAChief Financial Officer | $520,100 | $493,080 | $2,395,588 | $331,759 | $12,822 | $3,753,349 |
| Chandra Vargeese, Ph.D.Chief Technology Officer, Head of Platform Discovery Sciences | $502,200 | $434,380 | $2,129,411 | $320,341 | $14,064 | $3,400,396 |
| Christopher Francis, Ph.D.Chief Strategy Officer | $451,400 | $293,500 | $1,435,451 | $274,226 | $11,310 | $2,465,887 |
What changed and why
- 12,277,916 was Paul Bolno’s 2025 total compensation, compared with 4,272,299 in 2024.
- 10,926,840 of Bolno’s 2025 compensation was grant-date fair value of equity awards.
- 1,000,000 options and 121,000 RSUs were granted to Bolno in 2025; both award types vest over four years.
- 50:1 was the 2025 CEO-to-median-employee pay ratio; median employee compensation was 246,065.
- 2025 cash incentive compensation was reported for all four named executives; the table includes no separate bonus column.
Other Wave Life Sciences proxy statements
- 2025 proxy statement
Paul B. Bolno, M.D., MBA paid $4.3M (+10% on the year).
Filed Jun 23, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.